$JANX News
Last published 3d ago
- 3d agoJANXJanux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune DiseaseBusiness WireSAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial clinical results from the Phase 1 study of JANX011 in healthy volunteers and outlined its planned clinical development strategy in autoimmune diseases. JANX011 is the first program from Janux’s propriet ...
- 3d agoJANXJANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy - JANUX THERAPEUTICS INCEarnings Call TranscriptsWelcome to the GenX Therapeutics GenX 011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Call. All participants will be in a listen-only mode. Later, we will conduct a question-and-answer session. I w
- 1w agoJANXJanux Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2mo agoJANXJanux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013Business Wire- JANX013 is a novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific designed to further enhance the durability of anti-tumor immune responses in combination with Janux’s PSMA-targeted T cell engager
- 3mo agoJANXJanux Therapeutics Reports Second Quarter 2026 Financial Results and Business HighlightsBusiness WireJANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts JANX014 Phase 1 study continues enrolling patients with metastatic castration-resistant prostate cancer
- 6mo agoJANXJanux Therapeutics Reports First Quarter 2026 Financial Results and Business HighlightsBusiness WireJANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011
- 6mo agoJANXJanux Therapeutics Announces Discontinuation of JANX008 Clinical DevelopmentBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of
- 7mo agoJANXJanux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014Business Wire-JANX014 expands Janux's PSMA tumor-activated T cell engager portfolio -JANX007 is the Company's lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program,
- 7mo agoJANXJanux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone PaymentBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its
- 8mo agoJANXJanux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsBusiness WireContinued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling
- 8mo agoJANXJanux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011Business WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed in a Phase 1
- 10mo agoJANXJanux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 StudyBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor
- 11mo agoJANXJanux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPCBusiness WirePhase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients Preliminary results are encouraging with deep PSA
- 11mo agoJANXJanux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPCBusiness WireThe virtual event will take place on Monday, December 1, 2025, at 4:30 PM ET Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel
- 1y agoJANXJanux Therapeutics Reports Third Quarter 2025 Financial Results and Business HighlightsBusiness WireEnrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the fourth quarter of 2025 $989.0 million in cash, cash equivalents, and short-term investments at end of third quarter
- 1y agoJANXJanux Therapeutics Reports Second Quarter 2025 Financial Results and Business HighlightsBusiness WireR&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases Enrollment ongoing for JANX007 and JANX008 Updates on JANX007
- 1y agoJANXJanux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With MerckBusiness WireFirst patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad
- 1y agoJANXJanux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D DayBusiness WirePSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds
- 1y agoJANXJanux Therapeutics to Host Virtual R&D Day on July 24, 2025Business WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
- 1y agoJANXJanux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development OfficerBusiness WireMs. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage
- 1y agoJANXJanux Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsBusiness WirePhase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients Updated JANX007 data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Enrollment ongoing for JANX007 and
- 1y agoJANXJanux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program UpdatesBusiness WirePhase 1b expansion study initiated in taxane-naïve mCRPC patients Updated data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Updates on JANX007 and JANX008 expected in the second half
- 1y agoJANXJanux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsBusiness WireRecently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC Enrollment ongoing for JANX007 and JANX008 Update on JANX007 and JANX008 data is anticipated in 2025 R&D Day is
- 1y agoJANXJanux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical OfficerBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
- 1y agoCGEMCRGXDCTHELVN+8Clear Street Launches Healthcare & Biotechnology Equity ResearchBusiness WireComprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a
- 1y agoJANXJanux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 MillionBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
- 1y agoJANXJanux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
- 1y agoJANXJanux Therapeutics Announces Proposed Public OfferingBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
- 1y agoJANXJanux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPCBusiness WireEmerging JANX007 data demonstrated substantial clinical activity in 5L mCRPC patients, supporting clinical development plan directed at pre-PLUVICTO® 2L / 3L patients In 16 patients JANX007 displayed: High
- 1y agoJANXJanux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion StudiesBusiness WireThe virtual event will take place on Monday, December 2, 2024, at 4:30 PM ET Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel
- 2y agoJANXJanux Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsBusiness WireEnrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2024 $658.0 million in
- 2y agoJANXJanux Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsBusiness WireEnrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 Appointed Eric
- 2y agoJANXJanux Therapeutics Announces Updates to Board of DirectorsBusiness WireThe appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of
- 2y agoONCYCADLAZNHALO+1Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to ClimbPR NewswireUSA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...
- 2y agoONCYCADLAZNHALO+1Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to ClimbPR NewswireIn the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...
- 2y agoJANXJanux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsBusiness WireEnrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H
- 2y agoJANXJanux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsBusiness WireRecently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr JANX008 in solid tumors Enrollment ongoing for JANX007 and JANX008 Update on JANX007 data and doses
- 2y agoJANXJanux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
- 2y agoJANXJanux Therapeutics Announces Proposed Public Offering of Common StockBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
- 2y agoJANXJanux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid TumorsBusiness WireEmerging JANX007 data illustrate a potential best-in-class profile: promising efficacy with favorable safety profile in heavily pretreated subjects with late-stage mCRPC 83% (5/6) of subjects achieved PSA50 declines
- 2y agoJANXJanux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008Business WireThe virtual event will take place on Monday, February 26th, 2024, at 4:30PM ET Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel
- 2y agoJANXJanux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific OfficerBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
- 3y agoJANXJanux Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsBusiness WireEnrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on clinical programs expected in 2024 $349.7 million in cash, cash
- 3y agoJANXJanux Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsBusiness WirePresented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer Management team bolstered with key appointment $303.3 million in cash, cash equivalents, and short-term
- 3y agoJANXJanux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
- 3y agoJANXJanux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline ProgramsBusiness WireMultiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels
- 3y agoJANXJanux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical DevelopmentBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
- 3y agoJANXJanux Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsBusiness Wire-First patient dosed with EGFR-TRACTr (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors- -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -$316.9 million in cash
- 3y agoJANXJanux Therapeutics to Participate at Upcoming May 2023 Investor ConferencesBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
- 3y agoJANXJanux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid TumorsBusiness WireJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell